Key result
This letter highlights that while the HDL-SPE assay was validated in humans, its performance in mice is limited, and the role of ApoE in HDL may differ substantially between mice and humans.
Answers are grounded in this paper and cite their sources.
Caution is warranted when interpreting HDL-SPE assay results from mouse models due to interspecies differences in ApoE function and assay validation.
The recent study by Martínez-Beamonte et al. provides new insights into how extra virgin olive oil enriched in bioactive compounds may exert anti-atherogenic effects, by improving high-density lipoprotein (HDL) function, as determined by the high-density lipoprotein-specific phospholipid efflux (HDL-SPE) assay in Apoe-deficient mice. We would like to highlight two points. First, the HDL-SPE assay was validated in human samples, but there is only limited data on how it performs in mice. Second, the role of ApoE in ApoA-I-containing HDL may differ substantially between mice and humans. The finding by Martínez-Beamonte et al. is quite intriguing, but it will be important to extend their findings in mice to human subjects.
No takes yet. Share an insight, caveat, or question.
Satō et al. (2026) reported a letter. This letter highlights that while the HDL-SPE assay was validated in humans, its performance in mice is limited, and the role of ApoE in HDL may differ substantially between mice and humans.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: